Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Go back to Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis| (NASDAQ: AUPH) | Delayed: 16.90 -0.06 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.96 | 52 Week High | $5.69 | |||
| Open | $16.93 | 52 Week Low | $1.42 | |||
| Day High | $17.03 | P/E | N/A | |||
| Day Low | $16.80 | EPS | $0.00 | |||
| Volume | 1,092,721 | |||||
